ML188

  Cat. No.:  DC33651   Featured
Chemical Structure
1417700-13-0
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
ML188 is a Potent Noncovalent Small Molecule Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. The X-ray structure of SARS-CoV 3CLpro bound with ML188 was instrumental in guiding subsequent rounds of chemistry optimiz
Cas No.: 1417700-13-0
Chemical Name: N-[(1R)-2-(tert-Butylamino)-2-oxo-1-pyridin-3-ylethyl]-N-(4-tert-butylphenyl)furan-2-carboxamide
Synonyms: ML188; ML-188; ML 188;
SMILES: O1C=CC=C1C(N([C@H](C1=CC=CN=C1)C(NC(C)(C)C)=O)C1=CC=C(C(C)(C)C)C=C1)=O
Formula: C26H31N3O3
M.Wt: 433.552
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: ML188, a first in class probe, is a selective non-covalent SARS-CoV 3CLpro inhibitor with an IC50 of 1.5 μM. Antiviral activity[1].
In Vitro: ML188 (0-30 μM; 48 hours) effectively inhibit SARS-CoV replication in cell culture[1]. Probe ML188 is a modest molecular weight SARS-CoV 3CLpro inhibitor with demonstrated antiviral activity and a non-covalent mechanism of action. ML188 yields an antiviral EC50 value ranging from 12.9 to 13.4 μM in mock-infected and SARS-CoV infected cells[1]. Cell Viability Assay[1] Cell Line: Vero E6 cells (mock-infected or infected with SARS-CoV) Concentration: 3, 4, 5, 8,10, 15, 20, 30 μM Incubation Time: 48 hour Result: Against mock-infected and SARS-CoV infected cells.
References: [1]. Jacobs J, et al. Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. J Med Chem. 2013 Jan 24;56(2):534-46.
MSDS
TITLE DOWNLOAD
MSDS_15962_DC33651_1417700-13-0
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC33651 ML188 ML188 is a Potent Noncovalent Small Molecule Inhibitor of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. The X-ray structure of SARS-CoV 3CLpro bound with ML188 was instrumental in guiding subsequent rounds of chemistry optimiz
DC10662 GC-376 GC376 is a novel, first-in-class, small molecule protease inhibitor with a favorable therapeutic index demonstrated in preclinical studies. A common feature of viruses in the picornavirus-like supercluster (including coronaviruses) is a 3C or 3C-like prot
DC20446 Mefuparib hydrochloride(CVL218) Mefuparib(CVL218) hydrochloride is a potent, highly selective, competitive PARP1/2 inhibitor with IC50 of 3.2/1.9 nM, respectively.CVL218 was more potent than Remdesivir in blocking Coronavirus infection of cells and equally as potent as Remdesivir in blocking replication of virus once it has entered the cells.
DC11407 Asapiprant(BGE-175) Asapiprant (BGE-175) is a potent and specific antagonist of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit
DC23957 RO-9187 A potent HCV NS5B RNA polymerase inhibitor.
DC22771 Proxalutamide Proxalutamide (GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) for the potential treatment of COVID-19, prostate cancer, and breast cancer.
X